To evaluate the requirement for IFNγ in antitumor responses driven by FS120m treatment, we treated MC38 tumor–bearing C57BL/6 mice with FS120m or isotype control and anti–IFNγ-blocking antibody (Fig. 4A). This evidence concerns the gene IFNG and neoplasm.